<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Clinical Practice</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Clinical Practice</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая практика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-3095</issn><issn publication-format="electronic">2618-8627</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95671</article-id><article-id pub-id-type="doi">10.17816/clinpract95671</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Association of the quality of life parameters with the indicators of chronic heart failure severity in patients with rheumatoid arthritis</article-title><trans-title-group xml:lang="ru"><trans-title>Ассоциации параметров качества жизни с показателями тяжести течения хронической сердечной недостаточности у пациентов с ревматоидным артритом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5188-7997</contrib-id><name-alternatives><name xml:lang="en"><surname>Ankudinov</surname><given-names>Andrey S.</given-names></name><name xml:lang="ru"><surname>Анкудинов</surname><given-names>Андрей Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>andruhin.box@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2708-3972</contrib-id><name-alternatives><name xml:lang="en"><surname>Kalyagin</surname><given-names>Alexey N.</given-names></name><name xml:lang="ru"><surname>Калягин</surname><given-names>Алексей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>akalagin@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Irkutsk State Medical University</institution></aff><aff><institution xml:lang="ru">Иркутский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Irkutsk Medical State University</institution></aff><aff><institution xml:lang="ru">Иркутский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2022-06-27" publication-format="electronic"><day>27</day><month>06</month><year>2022</year></pub-date><pub-date date-type="pub" iso-8601-date="2022-07-03" publication-format="electronic"><day>03</day><month>07</month><year>2022</year></pub-date><volume>13</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>29</fpage><lpage>36</lpage><history><date date-type="received" iso-8601-date="2022-01-10"><day>10</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-06-01"><day>01</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Ankudinov A.S., Kalyagin A.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Анкудинов А.С., Калягин А.Н.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Ankudinov A.S., Kalyagin A.N.</copyright-holder><copyright-holder xml:lang="ru">Анкудинов А.С., Калягин А.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://clinpractice.ru/clinpractice/article/view/95671">https://clinpractice.ru/clinpractice/article/view/95671</self-uri><abstract xml:lang="en"><p><bold><italic>Background:</italic></bold><italic> The quality of life of patients is one of determining factors in assessing the effectiveness of treatment and prognosis. A search for possible associations of the quality of life parameters with basic clinical indicators provides a possibility of a more detailed and comprehensive assessment of the patient’s condition, correction of therapy and an improvement in the prognosis. <bold>Aim:</bold> To carry out a comparative analysis of the quality of life parameters in patients with chronic heart failure (CHF) with preserved and moderately reduced left ventricular ejection fraction against the background of rheumatoid arthritis (RA) and without RA, as well as to identify possible associations of the quality of life indicators with the parameters of the CHF course. <bold>Methods:</bold> 134 CHF patients with an RA diagnosis were examined, as well as 122 CHF patients without RA. The functional class of CHF in patients participated in the study was I -II by NYHA. The diagnosis of RA was made on the basis of radiological and serological studies. The radiological stage of RA in patients included in the study was I -III, according to Steinbrocker. Methotrexate was the basic anti-inflammatory drug for the RA treatment. A comparative analysis of the CHF symptoms, morphofunctional parameters and their possible association with the quality of life indicators in patients with and without RA was performed. The processing was carried out using the Statistica 10.0 program. <bold>Results:</bold> In the group of patients with CHF and RA, in addition to the statistically significant differences in the standard clinical laboratory parameters, statistically significant differences were also revealed in the severity of pain syndrome, deterioration of role, physical and emotional functioning as compared to the CHF patients without RA. Besides, in the CHF/RA group, statistically significant associations were revealed between the severity of pain syndrome and the level of the left ventricular ejection fraction and left ventricular mass index. <bold>Conclusion:</bold> The severity of pain syndrome caused by RA in patients with CHF can negatively affect some morphological and functional parameters of the myocardium, which must be taken into account when managing this group of patients.</italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Обоснование.</italic></bold><italic> Качество жизни пациентов является одним из определяющих факторов, оценивающих эффективность лечения и прогноз. Поиск возможных ассоциаций параметров качества жизни с базовыми клиническими показателями — возможность более детальной и комплексной оценки состояния пациента, коррекции терапии и улучшения прогноза. <bold>Цель исследования</bold> — провести сравнительный анализ параметров качества жизни у пациентов с хронической сердечной недостаточностью (ХСН) с сохраненной и умеренно сниженной фракцией выброса левого желудочка на фоне ревматоидного артрита (РА) и без него, а также выявить возможные ассоциации показателей качества жизни с параметрами течения ХСН. <bold>Методы.</bold> Обследовано 134 пациента с ХСН на фоне РА и 122 пациента с ХСН без РА. Функциональный класс ХСН у принявших участие в исследовании пациентов — I–II по NYHA. Диагноз РА выставлен на основании рентгенологических и серологических исследований. Рентгенологическая стадия РА у включенных в исследование пациентов — I–III по Штейнброкеру. Базисный противовоспалительный препарат для лечения РА — метотрексат. Проводился сравнительный анализ симптомов ХСН, морфофункциональных параметров и их возможной ассоциации с показателями качества жизни у пациентов с/без РА. Обработка проводилась с использованием программы Statistica 10.0. <bold>Результаты.</bold> В группе пациентов с ХСН на фоне РА помимо статистически значимых различий в стандартных клинических лабораторных параметрах выявлены статистически значимые различия в выраженности болевого синдрома, ухудшения ролевого, физического и эмоционального функционирования по сравнению с пациентами с ХСН без РА. В группе ХСН на фоне РА выявлены также статистически значимые ассоциации выраженности болевого синдрома с уровнем фракции выброса левого желудочка и индексом массы левого желудочка. <bold>Заключение.</bold> Выраженность болевого синдрома, обусловленная РА, у пациентов с ХСН может негативно влиять на некоторые морфофункциональные параметры миокарда, что необходимо учитывать при ведении данной группы пациентов.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>rheumatoid arthritis</kwd><kwd>quality of life</kwd><kwd>correlation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>ревматоидный артрит</kwd><kwd>качество жизни</kwd><kwd>корреляция</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Shoemaker MJ, Dias KJ, Lefebvre KM, et al. Physical therapist clinical practice guideline for the management of individuals with heart failure. Physical Therapy. 2020;100(1):114–143. doi: 10.1093/ptj/pzz127</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Aune D, Schlesinger S, Leitzmann MF, et al. Physical activity and the risk of heart failure: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2021;36(4):367–381. doi: 10.1007/s10654-020-00693-6</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Osthoff R, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheumatic Dis. 2018; 77(9):1251–1260. doi: 10.1136/annrheumdis-2018-213585</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Metsios GS, Kitas GD. Physical activity, exercise and rheumatoid arthritis: Effectiveness, mechanisms and implementation. Best Pract Res Clin Rheumatol. 2018;32(5):669–682. doi: 10.1016/j.berh.2019.03.013</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Haedtke C, Smith M, Buren VJ, et al. The characteristics of pain in patients diagnosed with depression and heart failure. Pain Management Nursing. 2017;18(6):353–362. doi: 10.1016/j.pmn.2017.05.005</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Haedtke C, Smith M, Buren VJ, et al. The relationships among pain, depression, and physical activity in patients with heart failure. J Cardiovascular Nur. 2017;32(5):21–25. doi: 10.1097/JCN.0000000000000399</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ueno K, Kamiya K, Hamazaki N, et al. Usefulness of physical function sub-item of SF-36 survey to predict exercise intolerance in patients with heart failure. Eur J Cardiovascular Nur. 2021;(29): zvab052. doi: 10.1093/eurjcn/zvab052</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Клинические рекомендации: хроническая сердечная недостаточность. Российское кардиологическое общество. Национальное общество по изучению сердечной недостаточности и заболеваний миокарда. 2020. [Clinical recommendations: chronic heart failure. Russian Society of Cardiology. National Society for the Study of Heart Failure and Myocardial Diseases. 2020. (In Russ).] Режим доступа: http://cr.rosminzdrav.ru/schema/156. Дата обращения: 17.12.2021.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Насонов ЕЛ. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа, 2017. 464 с. [Nasonov EL. Rheumatology. Clinical recommendations. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ).]</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. Москва: МедиаСфера, 2002. 312 с. [Rebrova OY. Statistical analysis of medical data. Application of the STATISTICA application software package. Moscow: MediaSphere; 2002. 312 p. (In Russ).]</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Абдарахманова А.И., Зарипова Ф.А., Амиров Н.Б. Расстройства тревожно-депрессивного спектра при ревматических заболеваниях // Вестник современной клинической медицины. 2020. Т. 13, № 1. С. 61–65. [Abdarahmanova AI, Zaripova FA, Amirov NB. Disorders of the anxiety-depressive spectrum in rheumatic diseases. Bulletin Modern Clin Med. 2020;13(1):61–65. (In Russ).]</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ефремова Е.Ф., Шутов А.М., Бородулина Е.О. Проблема коморбидности при хронической сердечной недостаточности // Ульяновский медико-биологический журнал. 2015. № 4. С. 46–52. [Efremova EF, Shutov AM, Borodulina EO. The problem of comorbidity in chronic heart failure. Ulyanovsk Med Biol J. 2015; 4:46–52. (In Russ).]</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hollan I, Ronda N, Dessein P, et al. Lipid management in rheumatoid arthritis: a position paper by the cardiovascular pharmacotherapy working group of European society of cardiology. E Heart J Cardiovascular Pharmacotherapy. 2019;(6): 104–114. doi: 10.1093/ehjcvp/pvz033</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheumatic Dis. 2022; 81(6):768–779. doi: 10.1136/annrheumdis-2021-221733</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Logstrup BB, Masic D, Laurbjerg TB, et al. Left ventricular function at two-year follow-up in treatment-naive rheumatoid arthritis patients is associated with anti-cyclic citrullinated peptide antibody status: a cohort study. Scand J Rheumatol. 2017;46(6):432–440. doi: 10.1080/03009742.2016.1249941</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Nguyen TH, Fagerland MW, Deyab G, et al. Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis. PLoS ONE. 2021;16(6):e0253793. doi: 10.1371/journal.pone.0253793</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368</mixed-citation></ref></ref-list></back></article>
